Drug Trial Radar · NCT00235729
Lofexidine for Inpatient Opiate Detox
Last checked: Nov 20, 2026Latest source record: Mar 20, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
264
Actual
Start
Jun 2006
Primary completion
Oct 2007
Study completion Oct 2007
Sponsor
- Lead sponsor
- US Department of Veterans AffairsFederal agency
- Sponsor type
- Federal agency
- Collaborators
- National Institute on Drug Abuse (NIDA); USWM, LLC (dba US WorldMeds)
- First posted
- Oct 10, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to investigate the effectiveness of lofexidine in reducing withdrawal symptoms among subjects undergoing opiate detoxification. Currently, lofexidine is the most commonly used non-opiate medication for detoxification from opiates in the United Kingdom (UK). There is no non-opiate medication approved by the Food and Drug Administration (FDA) for the same indication in the United States (US). The only medications currently approved by the FDA for opiate detoxification are methadone and buprenorphine. These medications, however, have the potential to be abused. Lofexidine, on the other hand, offers a unique advantage for opiate detoxification because it is not addicting, is easy to use, and has a favorable safety profile.
Conditions
- Opiate Addiction
Interventions
LofexidineDrug
Lofexidine is an alpha2-adrenergic-agonist with mild to moderate antihypertensive actions. It is mainly used in the alleviation of opioid withdrawal signs and symptoms.
PlaceboDrug
Placebo is an exact match of lofexidine, less the active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SOWS-Gossop score on Day 3 during the treatment phase & time-to-dropout for the subjects in the two treatment groups. during the treatment phase.Time frame: Day 3 of treatment phase for the SOWs score. Time to dropout will be measured as the number of 6-hour time quadrants until a subject withdraws or completes the treatment phase of the study
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
CNS, Cerritos
Cerritos, California
CNS Psychiatric Institute of Washington
Washington D.C., District of Columbia
Atlanta Center for Medical Research
Atlanta, Georgia
Alexian Center for Psychiatric Research
Hoffman Estates, Illinois
University of Kentucky
Lexington, Kentucky
VA Maryland Health Care System, Baltimore
Baltimore, Maryland
Wayne State University School of Medicine
Detroit, Michigan
Richmond Medical Center
Staten Island, New York
VA Medical Center, Philadelphia
Philadelphia, Pennsylvania
VA Medical Center, Providence
Providence, Rhode Island
Psychiatric Hospital at Vanderbilt
Nashville, Tennessee
Research Across America
Dallas, Texas
University of Texas Health Science Center at San Antonio
San Antonio, Texas
VA Salt Lake City Health Care System, Salt Lake City
Salt Lake City, Utah
VA Puget Sound Health Care System, Seattle
Seattle, Washington
Aurora Psychiatric Hospital
Wauwatosa, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.